Response and long-term control of bone metastases after peptide receptor radionuclide therapy with 177Lu-octreotate

被引：0
|
作者：
Ezziddin, S. [1 ]
Sabet, A. [1 ]
Heinemann, F. [1 ]
Yong-Hing, C. [2 ]
Ahmadzadehfar, H. [1 ]
Guhlke, S. [1 ]
Hoeller, T. [1 ]
Willinek, W. [1 ]
Boy, C. [3 ]
Biersack, H. [1 ]
机构：
[1] Univ Hosp, Bonn, Germany
[2] Univ British Columbia Hosp, Vancouver, BC, Canada
[3] Univ Hosp, Essen, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S139 / S139
页数：1
相关论文
共 50 条
  • [31] Equivalent dose rate at 1m from patients after 177Lu-octreotate peptide receptor radionuclide therapy and its predictive factors
    Zhang-Yin, J. T.
    Guilabert, N.
    Calzada, M.
    Kiffel, T.
    Keller, I.
    Montravers, F.
    Lumbroso, J.
    Talbot, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S587 - S587
  • [32] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Arsenault, Frederic
    Saighi, Nassim
    Bouchard, Louis-Olivier
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (03) : 728 - 742
  • [33] Lesion segmentation in Somatostatin Receptor Imaging with 111In-Pentetreotide and 177Lu-Octreotate for Response Monitoring of Neuroendocrine Tumors (net) treated with 177Lu-Octreotate
    Rotger Regi, A.
    Duran Barquero, C.
    Ardila Mantilla, J.
    Lozano Murgas, L.
    Perez-Pascual, R.
    Percovich, J.
    Garcia Centeno, R.
    Blanco Codesido, M.
    Perez Diaz, D.
    Alonso Farto, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S597 - S597
  • [34] Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs)
    Del Prete, M.
    Buteau, F. A.
    Beauregard, J. M.
    NEUROENDOCRINOLOGY, 2016, 103 : 92 - 92
  • [35] Pitfalls in the Response Evaluation after Peptide Receptor Radionuclide Therapy with [177Lu-DOTA0, Tyr3]Octreotate
    Brabander, T.
    Van der Zwan, W.
    Teunissen, J.
    Kam, B.
    De Herder, W. W.
    Feelders, R.
    Krenning, E.
    Kwekkeboom, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 242 - 242
  • [36] Predicting Tumor-Absorbed Doses of 177Lu-Octreotate Peptide Receptor Radionuclide Therapy by Pretherapeutic 68Ga-DOTATOC PET
    Ezziddin, S.
    Lohmar, J.
    Yong-Hing, C.
    Sabet, A.
    Ahmadzadehfar, H.
    Biersack, H.
    Guhlke, S.
    Reichmann, K.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 198 (05)
  • [37] Pitfalls in the Response Evaluation After Peptide Receptor Radionuclide Therapy With [177Lu-DOTA0, Tyr3]Octreotate
    Brabander, Tessa
    Teunissen, Jaap
    Kam, Boen
    Krenning, Eric
    Kwekkeboom, Dik
    PANCREAS, 2017, 46 (03) : 438 - 438
  • [38] Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Brabander, Tessa
    van der Zwan, Wouter A.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    de herder, Wouter W.
    Feelders, Richard A.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    ENDOCRINE-RELATED CANCER, 2017, 24 (05) : 243 - 251
  • [39] Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: initial dosimetry and safety results of the P-PRRT trial
    Del Prete, Michela
    Buteau, Francois-Alexandre
    Beaulieu, Alexis
    Beauregard, Jean-Mathieu
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [40] Transcriptional response of kidney tissue after 177Lu-octreotate administration in mice
    Schuler, Emil
    Rudqvist, Nils
    Parris, Toshima Z.
    Langen, Britta
    Helou, Khalil
    Forssell-Aronsson, Eva
    NUCLEAR MEDICINE AND BIOLOGY, 2014, 41 (03) : 238 - 247
12345